Board of Directors
General Partner, Andreessen Horowitz
Jorge Conde was elected to the Tmunity board in 2019.
Mr. Conde is a General Partner at Andreessen Horowitz (a16z) where he leads investments at the cross section of biology, computer science and engineering. Prior to joining a16z, Mr. Conde served as Chief Strategy Officer for Syros (NASDAQ: SYRS), which is advancing a new wave of medicines that control expression of disease-driving genes to treat cancer and other diseases. He previously served as the company's Chief Financial Officer and Chief Product Officer, leading the platform strategy for Syros' novel gene regulation technology. Mr. Conde also cofounded Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Earlier in his career, Mr. Conde worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley. Mr. Conde holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in Biology from Johns Hopkins University. Mr. Conde was named one of the top 35 young innovators in the world by the MIT Technology Review and is a Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He previously served on the board of the Museum of Science, Boston.
Board member, Audit Committee Chair, Dicerna Pharmaceuticals, Inc.
Patrick Gray was elected to the Tmunity board in 2019.
Mr. Gray is a board member and chair of the Audit Committee at Dicerna Pharmaceuticals, Inc., a Lexington, MA based biopharmaceutical company which is traded on NASDAQ. He brings extensive experience in accounting and financial reporting to our board of directors, having spent over 37 years with PricewaterhouseCoopers LLP (“PwC”) until his retirement in 2009. He is a Certified Public Accountant who spent 25 years as an Audit Partner serving clients ranging from Fortune 500 companies and multi-national companies to rapid-growth companies pursuing an initial public offering. At the time of his retirement, he served as the lead partner for the PwC U.S. firm Corporate Governance Group. Prior to that time, he held various other leadership positions with the firm, including leadership of the PW (Price Waterhouse) High Tech Group. He previously served on the boards of directors of Civitas, Solutions, Inc. and Datto, Inc. Mr. Gray has been selected to serve on our board of directors because of his extensive experience in accounting, auditing, financial reporting, deep understanding of financial controls and familiarity with growing public companies, experience in leadership positions at PwC and public company governance experience as leader of the PwC’s corporate governance group. Mr. Gray holds a BS in Economics from The Wharton School of the University of Pennsylvania.
Partner, Lilly Asia Ventures
Judith Li was elected to the Tmunity board in 2018.
Ms. Li is a Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, she worked at McKinsey and Company’s New York office, focusing exclusively on pharmaceutical and medical devices, health insurance and healthcare provider engagements. She also worked at Partners Healthcare, Harvard University’s umbrella hospital network, where she focused on hospital administration, and co-founded a start-up focused on interventional nephrology. Ms. Li holds a Bachelor’s in biology from Harvard University and an MBA from Harvard University Business School.
Chair, Board of Directors, G1 Therapeutics
Garry Nicholson was elected to the Tmunity board in 2019.
Mr. Nicholson is Chair of G1 Therapeutics. Most recently, he served as President and Chief Executive Officer of XTuit Pharmaceuticals, where he also was a member of the board of directors. Prior to XTuit, Mr. Nicholson was President, Pfizer Oncology and was responsible for global commercialization and sales, clinical development and regulatory strategy, and business development. Prior to Pfizer, Mr. Nicholson also held various leadership positions in the oncology division of Eli Lilly and Company. He currently serves on the board of directors of G1 Therapeutics, Inc., Five Prime Therapeutics, Inc., SQZ Biotechnologies and Personal Genome Diagnostics. He was on the board of TESARO, Inc. which was acquired by GlaxoSmithKline in 2018. Mr. Nicholson holds an MBA from the University of South Carolina and earned his BS in Pharmacy at the University of North Carolina, Chapel Hill.
Founder and Chairman of the Parker Institute for Cancer Immunotherapy
Sean Parker was elected to the Tmunity board in 2018.
Mr. Parker is a philanthropist and entrepreneur with a record of launching genre-defining companies. He is the Founder and Chairman of the Parker Institute for Cancer Immunotherapy (PICI), the President of the Parker Foundation and Founder of the Economic Innovation Group. The Parker Institute for Cancer Immunotherapy was founded in 2016 and builds on Mr. Parker’s leadership in funding and promoting research into the relationship between the immune system and cancer. In the ensuing years, PICI has evolved into a leader in the immunotherapy field for cutting edge research collaboration and clinical development, including funding a landmark human trial using CRISPR technology. In addition to cancer research, Mr. Parker has led many initiatives that revolutionized the civic and social landscape. He was the co-founder of Napster at age 19 and of Plaxo at 21. In 2004 he partnered with Mark Zuckerberg to found Facebook and served as its first president.
Beth Seidenberg, MD
Founding Managing Director, Westlake Village BioPartners
Beth Seidenberg, MD was elected to the Tmunity board in 2018.
Dr. Seidenberg is a founding managing director of Westlake Village BioPartners and a general partner at Kleiner Perkins, a leading venture capital firm. A longtime life sciences investor, she has incubated-invested more than 20 biotech ventures. Dr. Seidenberg has a demonstrated ability to identify and accelerate medically meaningful molecules through development. Her expertise is grounded in her significant senior level industry experience with leadership roles at Amgen, Bristol-Myers Squibb and Merck Research Laboratories. Most recently, at Amgen, Dr. Seidenberg was chief medical officer and head of global development. Dr. Seidenberg holds a Bachelor of Science degree in biology and anthropology from Barnard College and attended medical school at the University of Miami School of Medicine. She completed her medical residency at Johns Hopkins University and the George Washington University, and Fellowship at the National Institutes of Health.
Partner, Ping An Ventures